Fibrosis - Pipeline Review, H1 2017
Fibrosis - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis – Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.
Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis – Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.
Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Fibrosis – Overview
Fibrosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrosis – Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Aelis Farma SAS
Allakos Inc
Anima Biotech Ltd
Bristol-Myers Squibb Company
Calypso Biotech SA
Complexa Inc
Encycle Therapeutics Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
iBio Inc
Immunomet Therapeutics Inc
Inception Sciences Inc
Insmed Inc
Inventiva
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Lycera Corp
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Ribomic Inc
Scholar Rock Inc
SciFluor Life Sciences LLC
SK Chemicals Co Ltd
UCB SA
VivaCell Biotechnology Espana SL
Fibrosis – Drug Profiles
ACE-2798 – Drug Profile
AEF-0118 – Drug Profile
AK-002 – Drug Profile
Antibody to Inhibit Transglutaminase 2 for Fibrosis – Drug Profile
CALY-001 – Drug Profile
CWHM-12 – Drug Profile
elafibranor – Drug Profile
G-XXX – Drug Profile
IB-DMD – Drug Profile
IBIOCFB-03 – Drug Profile
IM-156 – Drug Profile
INS-1007 – Drug Profile
ISTH-1106 – Drug Profile
IW-1701 – Drug Profile
IW-1973 – Drug Profile
LYC-53976 – Drug Profile
Monoclonal Antibodies for Fibrosis – Drug Profile
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis – Drug Profile
Monoclonal Antibody 2 for Fibrosis – Drug Profile
Monoclonal Antibody for Fibrotic Scar – Drug Profile
Monoclonal Antibody to Activate BMP7 for Fibrosis – Drug Profile
NCE-401 – Drug Profile
Neumomir – Drug Profile
NMIL-121 – Drug Profile
OCX-063 – Drug Profile
PAT-048 – Drug Profile
PL-5028 – Drug Profile
PRI-724 – Drug Profile
Proteins for Central Nervous System Disorders and Fibrosis – Drug Profile
RBM-003 – Drug Profile
RBM-007 – Drug Profile
Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis – Drug Profile
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders – Drug Profile
RG-6125 – Drug Profile
Small Molecule for Fibrosis – Drug Profile
Small Molecule for Fibrosis – Drug Profile
Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease – Drug Profile
Small Molecule to Inhibit LOXL2 for Fibrosis – Drug Profile
Small Molecule to Inhibit MicroRNA for Vascular Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis and Inflammatory Diseases – Drug Profile
Small Molecules for Fibrosis and Oncology – Drug Profile
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis – Drug Profile
Small Molecules to Antagonize Integrin Alpha V for Fibrosis – Drug Profile
Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease – Drug Profile
Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology – Drug Profile
Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology – Drug Profile
SRI-31277 – Drug Profile
ST-2001 – Drug Profile
Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology – Drug Profile
VCE-0048 – Drug Profile
X-165 – Drug Profile
XOMA-089 – Drug Profile
Fibrosis – Dormant Projects
Fibrosis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Fibrosis – Overview
Fibrosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrosis – Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Aelis Farma SAS
Allakos Inc
Anima Biotech Ltd
Bristol-Myers Squibb Company
Calypso Biotech SA
Complexa Inc
Encycle Therapeutics Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
iBio Inc
Immunomet Therapeutics Inc
Inception Sciences Inc
Insmed Inc
Inventiva
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Lycera Corp
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Ribomic Inc
Scholar Rock Inc
SciFluor Life Sciences LLC
SK Chemicals Co Ltd
UCB SA
VivaCell Biotechnology Espana SL
Fibrosis – Drug Profiles
ACE-2798 – Drug Profile
AEF-0118 – Drug Profile
AK-002 – Drug Profile
Antibody to Inhibit Transglutaminase 2 for Fibrosis – Drug Profile
CALY-001 – Drug Profile
CWHM-12 – Drug Profile
elafibranor – Drug Profile
G-XXX – Drug Profile
IB-DMD – Drug Profile
IBIOCFB-03 – Drug Profile
IM-156 – Drug Profile
INS-1007 – Drug Profile
ISTH-1106 – Drug Profile
IW-1701 – Drug Profile
IW-1973 – Drug Profile
LYC-53976 – Drug Profile
Monoclonal Antibodies for Fibrosis – Drug Profile
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis – Drug Profile
Monoclonal Antibody 2 for Fibrosis – Drug Profile
Monoclonal Antibody for Fibrotic Scar – Drug Profile
Monoclonal Antibody to Activate BMP7 for Fibrosis – Drug Profile
NCE-401 – Drug Profile
Neumomir – Drug Profile
NMIL-121 – Drug Profile
OCX-063 – Drug Profile
PAT-048 – Drug Profile
PL-5028 – Drug Profile
PRI-724 – Drug Profile
Proteins for Central Nervous System Disorders and Fibrosis – Drug Profile
RBM-003 – Drug Profile
RBM-007 – Drug Profile
Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis – Drug Profile
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders – Drug Profile
RG-6125 – Drug Profile
Small Molecule for Fibrosis – Drug Profile
Small Molecule for Fibrosis – Drug Profile
Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease – Drug Profile
Small Molecule to Inhibit LOXL2 for Fibrosis – Drug Profile
Small Molecule to Inhibit MicroRNA for Vascular Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis – Drug Profile
Small Molecules for Fibrosis and Inflammatory Diseases – Drug Profile
Small Molecules for Fibrosis and Oncology – Drug Profile
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis – Drug Profile
Small Molecules to Antagonize Integrin Alpha V for Fibrosis – Drug Profile
Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease – Drug Profile
Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology – Drug Profile
Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology – Drug Profile
SRI-31277 – Drug Profile
ST-2001 – Drug Profile
Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology – Drug Profile
VCE-0048 – Drug Profile
X-165 – Drug Profile
XOMA-089 – Drug Profile
Fibrosis – Dormant Projects
Fibrosis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fibrosis – Pipeline by Acceleron Pharma Inc, H1 2017
Fibrosis – Pipeline by Aelis Farma SAS, H1 2017
Fibrosis – Pipeline by Allakos Inc, H1 2017
Fibrosis – Pipeline by Anima Biotech Ltd, H1 2017
Fibrosis – Pipeline by Bristol-Myers Squibb Company, H1 2017
Fibrosis – Pipeline by Calypso Biotech SA, H1 2017
Fibrosis – Pipeline by Complexa Inc, H1 2017
Fibrosis – Pipeline by Encycle Therapeutics Inc, H1 2017
Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Fibrosis – Pipeline by Five Prime Therapeutics Inc, H1 2017
Fibrosis – Pipeline by Genfit SA, H1 2017
Fibrosis – Pipeline by GlycoMimetics Inc, H1 2017
Fibrosis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Fibrosis – Pipeline by iBio Inc, H1 2017
Fibrosis – Pipeline by Immunomet Therapeutics Inc, H1 2017
Fibrosis – Pipeline by Inception Sciences Inc, H1 2017
Fibrosis – Pipeline by Insmed Inc, H1 2017
Fibrosis – Pipeline by Inventiva, H1 2017
Fibrosis – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Fibrosis – Pipeline by Isarna Therapeutics GmbH, H1 2017
Fibrosis – Pipeline by Lycera Corp, H1 2017
Fibrosis – Pipeline by Neumedicines Inc, H1 2017
Fibrosis – Pipeline by Novartis AG, H1 2017
Fibrosis – Pipeline by Palatin Technologies Inc, H1 2017
Fibrosis – Pipeline by Ribomic Inc, H1 2017
Fibrosis – Pipeline by Scholar Rock Inc, H1 2017
Fibrosis – Pipeline by SciFluor Life Sciences LLC, H1 2017
Fibrosis – Pipeline by SK Chemicals Co Ltd, H1 2017
Fibrosis – Pipeline by UCB SA, H1 2017
Fibrosis – Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Fibrosis – Dormant Projects, H1 2017
Fibrosis – Dormant Projects, H1 2017 (Contd.1), H1 2017
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Products under Development by Companies, H1 2017 (Contd.2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd.1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fibrosis – Pipeline by Acceleron Pharma Inc, H1 2017
Fibrosis – Pipeline by Aelis Farma SAS, H1 2017
Fibrosis – Pipeline by Allakos Inc, H1 2017
Fibrosis – Pipeline by Anima Biotech Ltd, H1 2017
Fibrosis – Pipeline by Bristol-Myers Squibb Company, H1 2017
Fibrosis – Pipeline by Calypso Biotech SA, H1 2017
Fibrosis – Pipeline by Complexa Inc, H1 2017
Fibrosis – Pipeline by Encycle Therapeutics Inc, H1 2017
Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Fibrosis – Pipeline by Five Prime Therapeutics Inc, H1 2017
Fibrosis – Pipeline by Genfit SA, H1 2017
Fibrosis – Pipeline by GlycoMimetics Inc, H1 2017
Fibrosis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Fibrosis – Pipeline by iBio Inc, H1 2017
Fibrosis – Pipeline by Immunomet Therapeutics Inc, H1 2017
Fibrosis – Pipeline by Inception Sciences Inc, H1 2017
Fibrosis – Pipeline by Insmed Inc, H1 2017
Fibrosis – Pipeline by Inventiva, H1 2017
Fibrosis – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Fibrosis – Pipeline by Isarna Therapeutics GmbH, H1 2017
Fibrosis – Pipeline by Lycera Corp, H1 2017
Fibrosis – Pipeline by Neumedicines Inc, H1 2017
Fibrosis – Pipeline by Novartis AG, H1 2017
Fibrosis – Pipeline by Palatin Technologies Inc, H1 2017
Fibrosis – Pipeline by Ribomic Inc, H1 2017
Fibrosis – Pipeline by Scholar Rock Inc, H1 2017
Fibrosis – Pipeline by SciFluor Life Sciences LLC, H1 2017
Fibrosis – Pipeline by SK Chemicals Co Ltd, H1 2017
Fibrosis – Pipeline by UCB SA, H1 2017
Fibrosis – Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Fibrosis – Dormant Projects, H1 2017
Fibrosis – Dormant Projects, H1 2017 (Contd.1), H1 2017
LIST OF FIGURES
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
COMPANIES MENTIONED
Acceleron Pharma Inc
Aelis Farma SAS
Allakos Inc
Anima Biotech Ltd
Bristol-Myers Squibb Company
Calypso Biotech SA
Complexa Inc
Encycle Therapeutics Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
iBio Inc
Immunomet Therapeutics Inc
Inception Sciences Inc
Insmed Inc
Inventiva
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Lycera Corp
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Ribomic Inc
Scholar Rock Inc
SciFluor Life Sciences LLC
SK Chemicals Co Ltd
UCB SA
VivaCell Biotechnology Espana SL
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
COMPANIES MENTIONED
Acceleron Pharma Inc
Aelis Farma SAS
Allakos Inc
Anima Biotech Ltd
Bristol-Myers Squibb Company
Calypso Biotech SA
Complexa Inc
Encycle Therapeutics Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
iBio Inc
Immunomet Therapeutics Inc
Inception Sciences Inc
Insmed Inc
Inventiva
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Lycera Corp
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Ribomic Inc
Scholar Rock Inc
SciFluor Life Sciences LLC
SK Chemicals Co Ltd
UCB SA
VivaCell Biotechnology Espana SL
